Drug Targeting and Nanomedicine: Lessons Learned from Liver Targeting and Opportunities for Drug Innovation
Drug targeting and nanomedicine are different strategies for improving the delivery of drugs to their target. Several antibodies, immuno-drug conjugates and nanomedicines are already approved and used in clinics, demonstrating the potential of such approaches, including the recent examples of the DN...
Main Authors: | Anna Salvati, Klaas Poelstra |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-01-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/1/217 |
Similar Items
-
Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches
by: Omima S. Mohammed, et al.
Published: (2023-11-01) -
Recent Advances in Nanomedicine for the Diagnosis and Therapy of Liver Fibrosis
by: Xue Bai, et al.
Published: (2020-09-01) -
Hitting the Target! Challenges and Opportunities for TGF-β Inhibition for the Treatment of Cardiac fibrosis
by: Maria Vistnes
Published: (2024-02-01) -
Interstitial lung disease: Does it matter what we call you, or what you look like, or how you behave?
by: R van Zyl-Smit, et al.
Published: (2023-08-01) -
Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges
by: Junxia Liu, et al.
Published: (2023-06-01)